This database contains 370 studies, archived under the term: "treatment outcome"
Click here to filter this large number of results.
Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study
Muresanu, Dafin F.,
Alvarez, X. Anton,
Moessler, Herbert,
Novak, Philipp H.,
Stan, Adina,
Buzoianu, Anca,
Bajenaru, Ovidiu,
Popescu, Bogdan O.
The maintenance of the effects of Cerebrolysin, a peptidergic compound with neurotrophic activity, on cognitive performance and qEEG activity was investigated through a 12-week, open-label extension of a 4-week, randomised, placebo-controlled pilot study. Thirty-three out of 41 patients with mild-to-moderate severe probable vascular dementia (VaD) according to NINDS-AIREN participating in the double-blind phase of the […]
Effects of rivastigmine on common symptomatology of Alzheimer’s disease (EXPLORE)
Objective: To evaluate, in a real-world clinical setting, the efficacy of rivastigmine in the management of six symptoms commonly associated with Alzheimer’s disease (AD).; Methods: This was a naturalistic, prospective, open-label, multi-centre, post-marketing, observational study. Data were collected by the participating study physicians at their practices across Canada. Subjects had a clinical diagnosis of mild-to-moderate […]
The synergistic effect of acupuncture and computer-based cognitive training on post-stroke cognitive dysfunction: a study protocol for a randomized controlled trial of 2 × 2 factorial design
Yang, Shanli,
Ye, Haicheng,
Huang, Jia,
Tao, Jing,
Jiang, Cai,
Lin, Zhicheng,
Zheng, Guohua,
Chen, Lidian
Background: Stroke is one of the most common causes of cognitive impairment. Up to 75% of stroke survivors may be considered to have cognitive impairment, which severely limit individual autonomy for successful reintegration into family, work and social life. The clinical efficacy of acupuncture with Baihui (DU20) and Shenting (DU24) in stroke and post-stroke cognitive […]
Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial
Wang, Tao,
Huang, Qiu,
Reiman, Eric M.,
Chen, Kewei,
Li, Xia,
Li, Guanjun,
Lin, Zhiguang,
Li, Chunbo,
Xiao, Shifu
Most experts consider that memantine has a symptomatic treatment, but clinical trials have not yet provided compelling evidence to support a disease-modifying effect. We investigate the effects of memantine on clinical ratings; fluorodeoxyglucose positron emission tomography (FDG-PET) measurements, which can monitor disease-modifying effect; and cerebrospinal fluid (CSF) assays in patients with moderate to severe probable […]
Rivastigmine patch for treatment of Alzheimer’s disease in clinical practice in Thailand
Kulkantrakorn, Kongkiat,
Tanyakitpisal, Panas,
Towanabut, Somchai,
Dejthevaporn, Charungthai,
Rangseekajee, Poonsri,
Pongpakdee, Sunsanee,
Laptikultham, Somsak,
Rodprasert, Kritsada,
Setthawatcharawanich, Suwanna,
Thinkhamrop, Bandit
Background: Rivastigmine is a cholinesterase inhibitor for treatment of mild to moderate Alzheimer’s disease (AD) and dementia associated with Parkinson’s disease. The new patch formulation was recently made available. We assessed the safety, tolerability, and cognitive outcome of rivastigmine patch in treatment of mild to moderate AD in clinical practice in Thailand.; Methods: A multicentre, […]
An open-label, nonplacebo-controlled study on Cistanche tubulosa glycoside capsules (Memoregain(®)) for treating moderate Alzheimer’s Disease
Guo, Qihao,
Zhou, Yan,
Wang, Chao-Jih,
Huang, Young-Ming,
Lee, Yi-Ta,
Su, Muh-Hwan,
Lu, Jiahong
Aim: Efficacy and safety of Cistanche tubulosa glycoside capsules (CTG capsule, Memoregain(®)) for treating Alzheimer’s disease (AD) were studied.; Methods: A total of 18 patients with AD administered with Memoregain(®) for 48 weeks were assessed for drug efficacy by Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog), Mini-Mental State Examination (MMSE), Activities of Daily Living (ADLs), Blessed […]
Treadmill training as an augmentation treatment for Alzheimer’s disease: a pilot randomized controlled study
Arcoverde, Cynthia,
Deslandes, Andrea,
Moraes, Helena,
Almeida, Cloyra,
Araujo, Narahyana Bom de,
Vasques, Paulo Eduardo,
Silveira, Heitor,
Laks, Jerson
Objective: To assess the effect of aerobic exercise on the cognition and functional capacity in Alzheimer’s disease (AD) patients.; Method: Elderly (n=20) with mild dementia (NINCDS-ADRDA/CDR1) were randomly assigned to an exercise group (EG) on a treadmill (30 minutes, twice a week and moderate intensity of 60% VO₂max) and control group (GC) 10 patients. The […]
Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo-controlled trial
Akhondzadeh, S.,
Sabet, M. Shafiee,
Harirchian, M. H.,
Togha, M.,
Cheraghmakani, H.,
Razeghi, S.,
Hejazi, S. Sh,
Yousefi, M. H.,
Alimardani, R.,
Jamshidi, A.,
Zare, F.,
Moradi, A.
What Is Known: Herbal medicines have been used in the treatment of behavioural and psychological symptoms of dementia but with variable response. Crocus sativus (saffron) may inhibit the aggregation and deposition of amyloid β in the human brain and may therefore be useful in Alzheimer’s disease (AD).; Objective: The goal of this study was to […]
Effects of aerobic exercise on mild cognitive impairment: a controlled trial
Baker, Laura D.,
Frank, Laura L.,
Foster-Schubert, Karen,
Green, Pattie S.,
Wilkinson, Charles W.,
McTiernan, Anne,
Plymate, Stephen R.,
Fishel, Mark A.,
Watson, G. Stennis,
Cholerton, Brenna A.,
Duncan, Glen E.,
Mehta, Pankaj D.,
Craft, Suzanne
Objectives: To examine the effects of aerobic exercise on cognition and other biomarkers associated with Alzheimer disease pathology for older adults with mild cognitive impairment, and assess the role of sex as a predictor of response.; Design: Six-month, randomized, controlled, clinical trial.; Setting: Veterans Affairs Puget Sound Health Care System clinical research unit.; Participants: Thirty-three […]